Viromed AG Shares Strategic Update on MedTech Advancements

Viromed Medical AG, a leader in cold plasma technology, has reiterated its commitment to sustainable growth in the global MedTech market. The company's focus remains on innovative medical devices and translational research, particularly in addressing severe respiratory diseases like ventilator-associated pneumonia.

Significant progress has been made with the development of ViroCAP®, for wound healing, and PulmoPlas®, a unique system for pneumology. PulmoPlas® represents a potential scalable platform for future medical applications.

Viromed collaborates with top research institutions and maintains strategic partnerships in Europe, Korea, and Turkey. These efforts support the company's long-term growth strategy, emphasizing medical benefit and clinical relevance. Market acceptance for ViroCAP® is already strong, signaling promising advancements in cold plasma technology.